Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus VaccineMarch 30th 2023
The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.
Risankizumab Meets Primary Endpoint of Clinical Remission for Moderate to Severe Ulcerative ColitisMarch 28th 2023
The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.
Yescarta Demonstrates Improvement in Overall Survival Compared to Standard of Care in Lymphoma TreatmentMarch 27th 2023
Axicabtagene ciloleucel demonstrated a 2.5-fold increase in individuals with relapsed/refractory large B-cell lymphoma who were alive at 2 years and did not experience either cancer progression or require the need for additional cancer treatment.
FDA Approves Rezafungin Injection for the Treatment of Candidemia, Invasive CandidiasisMarch 24th 2023
Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.